Immunoprecise Antibodies Stock Performance
| IPA Stock | USD 0.38 0.03 8.57% |
The company retains a Market Volatility (i.e., Beta) of -1.4, which attests to a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Immunoprecise Antibodies are expected to decrease by larger amounts. On the other hand, during market turmoil, Immunoprecise Antibodies is expected to outperform it. At this point, Immunoprecise Antibodies has a negative expected return of -0.91%. Please make sure to check out Immunoprecise Antibodies' maximum drawdown, daily balance of power, period momentum indicator, as well as the relationship between the skewness and day typical price , to decide if Immunoprecise Antibodies performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Immunoprecise Antibodies has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Last Split Factor 1:5 | Dividend Date 2020-11-23 | Last Split Date 2020-11-23 |
1 | ImmunoPrecise Antibodies Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 | 09/16/2024 |
2 | Trust in Media Cooperative and Information Professional Association To Host Symposium on Information Quality in the Age of Generative AI | 10/03/2024 |
3 | ImmunoPrecise Advances Anti-Aging Research with Mayo Clinic Study, Poised to Tap into 81 Billion Market with AI Technology | 10/28/2024 |
4 | ImmunoPrecise soutient la recherche antivieillissement dans le cadre dune tude de la Mayo Clinic et sapprte entrer dans un march de 81 milliards de dollars avec... | 10/29/2024 |
5 | ImmunoPrecise to Host TECHDAY Cutting-Edge AI and Biologics Innovation | 11/04/2024 |
6 | ImmunoPrecise annonce son TECHDAY, un vnement ddi linnovation de pointe en matire dIA et de produits biologiques | 11/05/2024 |
7 | CareCloud, Inc. Q3 Earnings and Revenues Miss Estimates | 11/12/2024 |
8 | 20 Billion Market Breakthrough IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer Therapies | 11/13/2024 |
9 | Curis Reports Q3 Loss, Tops Revenue Estimates | 11/14/2024 |
10 | Marcus Millichaps Institutional Property Advisors Brokers Three Multifamily Property Sales in Tacoma for 102.6 Million | 11/21/2024 |
| Begin Period Cash Flow | 8.4 M |
Immunoprecise |
Immunoprecise Antibodies Relative Risk vs. Return Landscape
If you would invest 79.00 in Immunoprecise Antibodies on August 25, 2024 and sell it today you would lose (41.00) from holding Immunoprecise Antibodies or give up 51.9% of portfolio value over 90 days. Immunoprecise Antibodies is generating negative expected returns assuming volatility of 6.5518% on return distribution over 90 days investment horizon. In other words, 58% of stocks are less volatile than Immunoprecise, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Immunoprecise Antibodies Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Immunoprecise Antibodies' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Immunoprecise Antibodies, and traders can use it to determine the average amount a Immunoprecise Antibodies' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1387
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | IPA |
Estimated Market Risk
| 6.55 actual daily | 58 58% of assets are less volatile |
Expected Return
| -0.91 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.14 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Immunoprecise Antibodies is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Immunoprecise Antibodies by adding Immunoprecise Antibodies to a well-diversified portfolio.
Immunoprecise Antibodies Fundamentals Growth
Immunoprecise Stock prices reflect investors' perceptions of the future prospects and financial health of Immunoprecise Antibodies, and Immunoprecise Antibodies fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Immunoprecise Stock performance.
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.13 | ||||
| Profit Margin | (1.15) % | ||||
| Operating Margin | (0.86) % | ||||
| Current Valuation | 19.56 M | ||||
| Shares Outstanding | 28.83 M | ||||
| Price To Book | 0.46 X | ||||
| Price To Sales | 0.45 X | ||||
| Revenue | 24.52 M | ||||
| Gross Profit | 11.56 M | ||||
| EBITDA | (22.95 M) | ||||
| Net Income | (27.18 M) | ||||
| Cash And Equivalents | 19.24 M | ||||
| Cash Per Share | 0.77 X | ||||
| Total Debt | 13.68 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 5.06 X | ||||
| Book Value Per Share | 1.20 X | ||||
| Cash Flow From Operations | (4.25 M) | ||||
| Earnings Per Share | (0.77) X | ||||
| Market Capitalization | 10.84 M | ||||
| Total Asset | 59.99 M | ||||
| Retained Earnings | (100.27 M) | ||||
| Working Capital | 3.36 M | ||||
About Immunoprecise Antibodies Performance
By analyzing Immunoprecise Antibodies' fundamental ratios, stakeholders can gain valuable insights into Immunoprecise Antibodies' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Immunoprecise Antibodies has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Immunoprecise Antibodies has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.95) | (1.39) | |
| Return On Capital Employed | (0.27) | 0.18 | |
| Return On Assets | (0.45) | (1.35) | |
| Return On Equity | (0.80) | 0.30 |
Things to note about Immunoprecise Antibodies performance evaluation
Checking the ongoing alerts about Immunoprecise Antibodies for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Immunoprecise Antibodies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Immunoprecise Antibodies generated a negative expected return over the last 90 days | |
| Immunoprecise Antibodies has high historical volatility and very poor performance | |
| Immunoprecise Antibodies has some characteristics of a very speculative penny stock | |
| Immunoprecise Antibodies has a very high chance of going through financial distress in the upcoming years | |
| The company reported the last year's revenue of 24.52 M. Reported Net Loss for the year was (27.18 M) with profit before taxes, overhead, and interest of 11.56 M. | |
| Immunoprecise Antibodies has about 19.24 M in cash with (4.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.77, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Immunoprecise Antibodies has a poor financial position based on the latest SEC disclosures | |
| Roughly 12.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: Marcus Millichaps Institutional Property Advisors Brokers Three Multifamily Property Sales in Tacoma for 102.6 Million |
- Analyzing Immunoprecise Antibodies' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Immunoprecise Antibodies' stock is overvalued or undervalued compared to its peers.
- Examining Immunoprecise Antibodies' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Immunoprecise Antibodies' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Immunoprecise Antibodies' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Immunoprecise Antibodies' stock. These opinions can provide insight into Immunoprecise Antibodies' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Immunoprecise Stock analysis
When running Immunoprecise Antibodies' price analysis, check to measure Immunoprecise Antibodies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunoprecise Antibodies is operating at the current time. Most of Immunoprecise Antibodies' value examination focuses on studying past and present price action to predict the probability of Immunoprecise Antibodies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunoprecise Antibodies' price. Additionally, you may evaluate how the addition of Immunoprecise Antibodies to your portfolios can decrease your overall portfolio volatility.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |